32 results on '"Schalm, Stefanie"'
Search Results
2. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease
3. P464: PULSE DOSING OF POTENT AND SELECTIVE HETEROBIFUNCTIONAL MDM2 DEGRADER KT-253 DRIVES TUMOR REGRESSION AND DEMONSTRATES DIFFERENTIATED PHARMACOLOGY COMPARED TO P53/MDM2 SMALL MOLECULE INHIBITORS.
4. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
5. Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
6. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
7. Abstract 3934: KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
8. Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC
9. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
10. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
11. BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations
12. Proteolytic processing of protocadherin proteins requires endocytosis
13. Phosphorylation of protocadherin proteins by the receptor tyrosine kinase Ret
14. Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma
15. Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)
16. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
17. Abstract B127: Evaluating PRKACA as a therapeutic target for Fibrolamellar Carcinoma
18. 78 - BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations
19. Abstract 954: The landscape of kinase fusions in cancer
20. Abstract 2296: IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition
21. The landscape of kinase fusions in cancer
22. Molecular Mechanism of mTOR downstream signaling
23. Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes
24. Abstract LB-164: IDH mutations and tumorgenicity
25. Characterization of a Conserved C-terminal Motif (RSPRR) in Ribosomal Protein S6 Kinase 1 Required for Its Mammalian Target of Rapamycin-dependent Regulation
26. PI3-kinase and TOR: PIKTORing cell growth
27. TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function
28. Identification of a Conserved Motif Required for mTOR Signaling
29. Regulation of Ribosomal S6 Kinase 2 by Effectors of the Phosphoinositide 3-Kinase Pathway
30. Ribosomal S6 Kinase 2 Inhibition by a Potent C-terminal Repressor Domain Is Relieved by Mitogen-activated Protein-Extracellular Signal-regulated Kinase Kinase-regulated Phosphorylation
31. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation.
32. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.